​

Iterum Therapeutics (ITRM) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

ITRM Stock Rating

Iterum Therapeutics stock's rating consensus is Hold, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 1 Buy (25.00%), 3 Hold (75.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 4 0 3 1 Strong Sell Sell Hold Buy Strong Buy

ITRM Price Target Upside V Benchmarks

TypeNameUpside
StockIterum Therapeutics-
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.00$1.00$1.00
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 252----2
May, 251----1
Apr, 252----2
Feb, 252----2
Jan, 252----2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 10, 2024H.C. WainwrightBuyBuyhold
Aug 15, 2024H.C. WainwrightBuyBuyhold
Feb 07, 2024H.C. WainwrightBuyupgrade

Financial Forecast

EPS Forecast

$-6 $-4 $-2 $0 $2 $4 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.96$-1.26----
Avg Forecast$-2.96$-1.15$-0.64$-0.51$0.07$1.76
High Forecast$-0.10$-0.04$-0.02$-0.45$0.18$3.46
Low Forecast$-5.81$-2.26$-1.26$-0.57$-0.04$0.06
Surprise %-9.57%----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast$779.00K$3.02M$11.67M$29.18M$71.84M$151.61M
High Forecast$1.36M$5.26M$20.33M$50.84M$125.19M$264.21M
Low Forecast$200.46K$776.63K$3.00M$7.51M$18.49M$39.01M
Surprise %------

Net Income Forecast

$-100M $-70M $-40M $-10M $20M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-38.37M$-24.77M----
Avg Forecast$-38.37M$-14.91M$-8.30M$-6.61M$907.37K$22.81M
High Forecast$-1.32M$-514.76K$-286.48K$-5.86M$2.27M$44.84M
Low Forecast$-75.28M$-29.30M$-16.31M$-7.36M$-453.68K$787.81K
Surprise %-66.19%----

ITRM Forecast FAQ

Is Iterum Therapeutics stock a buy?

Iterum Therapeutics stock has a consensus rating of Hold, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 1 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Iterum Therapeutics is a neutral investment for most analysts.

What is Iterum Therapeutics's price target?

Iterum Therapeutics's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.

How does Iterum Therapeutics stock forecast compare to its benchmarks?

Iterum Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Iterum Therapeutics over the past three months?

  • June 2025: 100.00% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 100.00% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 100.00% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Iterum Therapeutics’s EPS forecast?

Iterum Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.64, marking a -49.21% decrease from the reported $-1.26 in 2024. Estimates for the following years are $-0.51 in 2026, $0.07 in 2027, and $1.76 in 2028.

What is Iterum Therapeutics’s revenue forecast?

Iterum Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $11.67M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $29.18M, followed by $71.84M for 2027, and $151.61M for 2028.

What is Iterum Therapeutics’s net income forecast?

Iterum Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-8.296M, representing a -66.51% decrease from the reported $-24.774M in 2024. Projections indicate $-6.611M in 2026, $907.37K in 2027, and $22.81M in 2028.